The recent merger of Lenoir-based Greer Laboratories with France-based Stallergenes is aimed at creating a fully integrated, global biopharmaceutical company, the company’s chairman and chief executive officer says.
During a webcast business update, CEO Fereydoun Firouz said the business model of Stallergenes Greer will allow the company to glow globally in the expanding allergy immunotherapy (AIT) market.